Navigation Links
Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
Date:5/15/2013

JERSEY CITY, N.J., May 15, 2013 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced its financial and operational results for the three and nine month periods ended March 31, 2013.  Complete financial results can be found in the Quarterly Report on Form 10-Q filed by Aoxing Pharma on May 15, 2013.

Financial Results:

Revenues for the three and nine months ended March 31, 2013 were $1,885,133 and $7,804,664, respectively, representing a 4% and a 43% increase over the revenues realized in the comparable periods of fiscal year 2012.  The increase in revenue was mainly attributable to the increase in sales of our main product, Zhongtongan, which is now being marketed for gynecological and orthopaedic applications in addition to its core pediatric and stomotological market.  Sales of Zhongtongan accounted for 91% of sales during the quarter ended March 31, 2013. 

Aoxing Pharma completed a $10.2 million financing at the end of September 2012, which allowed it to make some crucial investments in the future of its business.  Operating expenses, therefore, were swelled during the second and third quarters of fiscal 2013 by two categories of targeted investment:

  • Research and development ("R&D") expenses were $186,972 during the three months ended March 31, 2013 and $1,406,631 during the nine month period then ended, in both cases representing a significant increase over R&D expense in fiscal 2012. 
  • Selling expenses in the amount of $2,662,948 incurred during the three months ended March 31, 2013 and $4,977,821 during the nine months then ended were, in both cases, several fold higher than the selling
    '/>"/>

SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aoxing Pharmaceutical Company Announces Management Change
2. Aoxing Pharmaceutical Company, Inc. Declines To Comment On Market Activity
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For First Quarter Of 2013 Fiscal Year
4. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Second Quarter Of 2013 Fiscal Year
5. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
9. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
10. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
11. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
(Date:10/22/2014)... SAN DIEGO , Oct. 22, 2014 ... II medical device received 510 (k) OTC clearance by ... the AVACEN 100 to be marketed over the Internet ... with arthritis; muscle spasms; and minor strains and sprains ... The AVACEN 100 (MSRP $2495) is a ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
...  Leading events organiser UBM Live has revealed further ... Pharma Portfolio, CPhI Southeast Asia (SEA) 2012. Set to debut ... Indonesia, CPhI SEA is the first trade show and exhibition ... sector in the ASEAN region. CPhI SEA ...
... Conn., April 18, 2012   A new retrospective ... rates of intracranial hemorrhage (ICH), including both fatal and ... taken twice daily compared with warfarin. Results of the ... Journal of the American Heart Association. ...
Cached Medicine Technology:Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 2New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 3New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 4New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 5New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 6New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 7
(Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... News) -- Measures taken by Firestone officials at the ... have limited the spread of the disease there and ... Natural Rubber Co. provides health services to about 80,000 ... populated communities. Between Aug. 1 and Sept. 23, ... those 80,000 people. That incidence rate of 0.09 percent ...
(Date:10/20/2014)... 20, 2014 The newly updated Worldwide ... of thousands of facts, figures and forecasts on the ... medical sector forecast categories the Worldwide Medical Market ... and national views on the worldwide medical market to ... report gives you data for 2010-2019, covering each country ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... provide its comprehensive preventive care web service to STHS members and ... and motivate individuals to improve their health and safety. , ... ... a new partnership with eDoc4u , all eligible members and ...
... First Annual Diversity Council Honors Award(TM)RIDGEFIELD, Conn., ... top honor from the Association of Diversity ... Council Honors Award(TM). The award recognizes the ... diversity council groups that lead diversity processes ...
... Xevo TQ and Synapt HDMS Mass Spectrometers Target ... April 1 Waters Corporation (NYSE: ... Institute,s Center for Cancer Research in Bethesda, Md., ... and Waters ACQUITY(R) UPLC/Xevo(TM) TQ MS Systems for ...
... (AVP) receptor antagonist now available in new premixed ... Pharma US, Inc. today announced the commercial availability ... injection) Premixed in 5% Dextrose, a new premixed ... arginine vasopressin (AVP) receptor antagonist, is the first ...
... Eyecare Professionals Advise Diabetics on How to Minimize That ... Organization reports that 366 million cases of diabetes are ... because of the risk posed to healthy sight by ... Optical, Inc. reveals a dangerous lack of awareness about ...
... a drug took the fun out of stealing, would it ... 1st issue of Biological Psychiatry , published by Elsevier, ... is a type of impulse control disorder characterized by persistent ... an irresistible urge to steal items they often don,t even ...
Cached Medicine News:Health News:Nashville's eDoc4u Signs Partnership Agreement With Saint Thomas Health Services 2Health News:Nashville's eDoc4u Signs Partnership Agreement With Saint Thomas Health Services 3Health News:Boehringer Ingelheim Recognized For Diversity And Inclusion Efforts 2Health News:Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research 2Health News:Waters Corporation Announces the Purchase of UPLC/MS Systems by the National Cancer Institute for Advanced Metabolomics Research 3Health News:Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 2Health News:Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 3Health News:Astellas Launches Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia 4Health News:Lack of Awareness of Eye Health Risk Associated with Diabetes Poses Blinding Threat to Millions 2Health News:Lack of Awareness of Eye Health Risk Associated with Diabetes Poses Blinding Threat to Millions 3Health News:Lack of Awareness of Eye Health Risk Associated with Diabetes Poses Blinding Threat to Millions 4Health News:Suppressing the compulsion to steal 2
Carl Zeiss immersion oils are PCF free. They are quality controlled for two wavelengths of light, Ne=1.518 and Nd=1.515 at 23ºC....
Immersion oils may crystallize on storage. Can be redissolved on heating to 50ºC (1-2 hours)...
... Oils are the standard - the ones to ... Laboratories has consistently led in the development and ... Here is the record: , When the FDA ... of In Vitro Diagnostics in the 1970's, Cargille ...
... an Informatics software product enabling quick and ... the laboratory. With SpecTRACK Software, users can ... specimen from all laboratories in their LAN ... or cold room. Automate your existing manual ...
Medicine Products: